Myocardial Infarction Triage and Intervention Project (MITI)
Completed
National Heart, Lung, and Blood Institute (NHLBI)
Phase 3
1988-04-01
To determine the practicality, benefit, and safety of paramedic administration of
thrombolytic therapy for acute myocardial infarction. The feasibility of paramedics correctly
identifying candidates for thrombolytic therapy following myocardial infarction was assessed
in Phase I. In Phase II, pre-hospital thrombolytic therapy was compared with in-hospital
thrombolytic therapy.
Myocardial Infarction Triage and Intervention Project (MITI)
Completed
University of Washington
Phase 3
1988-04-01
To determine the practicality, benefit, and safety of paramedic administration of
thrombolytic therapy for acute myocardial infarction. The feasibility of paramedics correctly
identifying candidates for thrombolytic therapy following myocardial infarction was assessed
in Phase I. In Phase II, pre-hospital thrombolytic therapy was compared with in-hospital
thrombolytic therapy.
PROphylaxis for ThromboEmbolism in Critical Care Trial (PROTECT)
Completed
Australian and New Zealand Intensive Care Society Clinical Trials Group
Phase 3
2006-05-01
The purpose of this study is to evaluate the effect of Low Molecular Weight Heparin (LMWH)
(Fragmin, dalteparin) versus Unfractionated Heparin (UFH) on the primary outcome of proximal
leg Deep Vein Thrombosis (DVT) diagnosed by compression ultrasound, and the secondary
outcomes of Pulmonary Embolism (PE), bleeding, Heparin-Induced Thrombocytopenia (HIT), and
objectively confirmed venous thrombosis at any site.
PROphylaxis for ThromboEmbolism in Critical Care Trial (PROTECT)
Completed
Canadian Critical Care Trials Group
Phase 3
2006-05-01
The purpose of this study is to evaluate the effect of Low Molecular Weight Heparin (LMWH)
(Fragmin, dalteparin) versus Unfractionated Heparin (UFH) on the primary outcome of proximal
leg Deep Vein Thrombosis (DVT) diagnosed by compression ultrasound, and the secondary
outcomes of Pulmonary Embolism (PE), bleeding, Heparin-Induced Thrombocytopenia (HIT), and
objectively confirmed venous thrombosis at any site.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
